GILD

Gilead’s core moat remains its scale and durability in HIV treatment, where high switching costs, payer access, and deep prescriber familiarity support resilient cash generation. Management is trying to widen the growth engine beyond virology by leaning harder into oncology; the April 7, 2026 agreement to acquire Tubulis (up to $5.0B total consideration) expands Gilead’s antibody-drug conjugate platform and pipeline optionality. The strategic logic is sound, but execution risk is meaningful given crowded oncology competition and long development timelines.

Financially, 2025 revenue was $29.443B (up from $28.754B in 2024), with Q4 2025 revenue of $7.925B and non-GAAP EPS of $1.86. Cash and marketable securities were $10.6B at December 31, 2025 and Q4 operating cash flow was $3.3B, indicating strong liquidity to fund R&D and deals. Valuation appears reasonable for a low-beta, cash-generative pharma: management guided 2026 product sales of $29.6B–$30.0B and non-GAAP EPS of $8.45–$8.85, but limited third-party coverage makes cross-checking consensus harder.

Over the next 12 months, the bull case is steady HIV fundamentals plus upside from HIV prevention (lenacapavir PrEP progress) and pipeline readouts that could re-rate the oncology portfolio. Key catalysts are delivery versus 2026 guidance and clearer evidence that oncology assets can offset future patent/LOE and competitive pressures; a key risk is that acquisitions like Tubulis dilute near-term returns if clinical data disappoints. Policy and pricing pressure (including IRA-related dynamics) remains a persistent headline risk for large-cap biopharma.

Recommendation: HOLD. The stock offers high-quality cash flows with clear 2026 earnings power, but the next leg of upside likely requires tangible oncology/PrEP validation rather than additional dealmaking alone.